Morphic Holding Inc

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

WALTHAM, Mass., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences:

Morphic Announces Participation in Upcoming Investor Conferences

AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties

Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 13.33% and 37.38%, respectively, for the quarter ended June 2020.

Morphic Holding, Inc. (MORF) Reports Q2 Loss, Tops Revenue Estimates

Company’s first IND accepted by FDA for MORF-057 in IBD  Phase 1 study expected to begin in third-quarter 2020  Positive data presented at DDW 2020 further support MORF-057 preclinical profile

Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results

Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Morphic Holding, Inc. (MORF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD

Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020

WALTHAM, Mass., June  18, 2020  (GLOBE NEWSWIRE) --  Morphic Therapeutic  (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, and Marc Schegerin, M.D., chief financial officer and chief operating officer, are scheduled to make a presentation at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference at 11:00 a.m. ET on Tuesday, June 23, 2020. Morphic will give an update on the company’s progress across its portfolio of oral small molecule integrin inhibitors.

Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference

WALTHAM, Mass., April  07, 2020  (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financial officer and chief operating officer. Dr. Schegerin was most recently chief financial officer of ArQule and joins Morphic with extensive experience in the biotechnology space spanning clinical and business development, strategy, finance and operations.

Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer

Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate

Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease

Morphic Holding Inc. (NASDAQ:MORF) is one of five fledgling biotechnology companies cited for their potential to develop a drug that generates more than $1 billion in sales, according to an article published by Kiplinger in July.

Morphic Holding Tabbed as Likely to Develop Blockbuster Drug

WALTHAM, Mass., Aug.  30, 2019  (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present a corporate overview at the Wells Fargo Securities 2019 Healthcare Conference on Thursday, September 5, 2019 at 3:05pm ET, in Boston.

Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference

Morphic Holding, Inc. (NASDAQ: MORF) made its public debut Thursday morning, opening at $18 after being priced at $15 per share.

Morphic Opens Above IPO Price

News for Morphic Holding Inc Stock (MORF)